Lisdexamfetamine (Vyvanse) — NZ Medication Guide | KiwiMeds

✅ Reviewed by Ramon Wong, BPharm, Registered Pharmacist (New Zealand) | May 2026 — This information is for educational purposes only and is not a substitute for personalised advice from your doctor or pharmacist. Always seek professional guidance before making changes to your medications.

Lisdexamfetamine (brand name: Vyvanse) is a prescription stimulant medication used to treat Attention Deficit Hyperactivity Disorder (ADHD) in adults and children. It is a prodrug of dexamphetamine — meaning it converts to the active compound after absorption, which helps produce a smoother, longer-lasting effect with lower abuse potential compared to immediate-release amphetamines.

What is lisdexamfetamine used for?

In New Zealand, Vyvanse is prescribed for:

• ADHD in adults — when other stimulant treatments have been ineffective or not tolerated
• ADHD in children (aged 6 and over) — as part of a comprehensive treatment programme including psychological and educational support

In some countries, lisdexamfetamine is also approved for Binge Eating Disorder (BED), but this indication is not established in NZ prescribing practice.

How does lisdexamfetamine work?

Lisdexamfetamine is an inactive prodrug. After being swallowed, it is absorbed through the gut and converted to dexamphetamine by enzymes in red blood cells. Dexamphetamine increases the release of dopamine and noradrenaline in the brain, which helps improve:

• Attention and focus
• Impulse control
• Task organisation and follow-through
• Hyperactivity and restlessness

Because lisdexamfetamine must be converted to its active form in the body, it has a more gradual onset and less abuse potential compared to taking dexamphetamine directly.

Vyvanse dose and how to take it

Available strengths in NZ: 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg capsules.

• Starting dose (adults and children 6+): Usually 20–30 mg once daily in the morning
• Titration: Dose may be increased by 10–20 mg every 1–2 weeks based on response
• Maximum dose: 70 mg per day
• Timing: Take in the morning — taking later in the day may cause insomnia
• Food: Can be taken with or without food; the capsule can be opened and the powder dissolved in water if swallowing is difficult
• Duration of effect: Typically 10–14 hours, which is longer than most other ADHD medications

How effective is Vyvanse for ADHD?

Lisdexamfetamine is one of the most extensively studied ADHD medications and is generally considered highly effective:

• Clinical trials show significant improvements in ADHD symptom scores compared to placebo in both adults and children
• The long duration of action (10–14 hours) makes it suitable for full school/work-day coverage without the “wearing off” effects of shorter-acting medications
• Because it is a prodrug, blood levels rise more gradually — many people report a smoother, less “stimulant-like” experience compared to immediate-release methylphenidate or dexamphetamine

Common side effects of lisdexamfetamine

• Decreased appetite (very common)
• Trouble sleeping (insomnia)
• Dry mouth
• Headache
• Irritability or mood changes
• Increased heart rate or blood pressure
• Nausea or stomach pain
• Weight loss (particularly in children — growth should be monitored)
• Anxiety or feeling jittery

Many side effects are dose-related and can be managed by adjusting the dose or timing of the medication.

Serious side effects and warnings

• Cardiovascular effects — stimulants can increase heart rate and blood pressure; not recommended in people with serious heart conditions, structural heart defects, or uncontrolled hypertension
• Psychiatric symptoms — may trigger or worsen anxiety, agitation, psychosis, or mania in people with underlying psychiatric conditions
• Growth suppression — in children, long-term stimulant use may slow height gain; regular monitoring of growth is recommended
• Dependence and misuse potential — Vyvanse is a Class B2 Controlled Drug in NZ; prescriptions are subject to strict regulations
• Serotonin syndrome — rare but serious; risk increases if combined with MAOIs or other serotonergic drugs

Who should not take lisdexamfetamine?

• People with significant cardiovascular disease (e.g., coronary artery disease, heart failure, arrhythmias)
• Uncontrolled hypertension
• Hyperthyroidism
• History of drug or alcohol dependence
• Bipolar disorder (may trigger mania) — use with caution
• Glaucoma
• Within 14 days of taking a monoamine oxidase inhibitor (MAOI)

Lisdexamfetamine and pregnancy / breastfeeding

Lisdexamfetamine is not recommended during pregnancy. Use during pregnancy has been associated with premature birth, low birth weight, and withdrawal symptoms in newborns. If you are planning a pregnancy or discover you are pregnant while taking Vyvanse, discuss stopping or switching treatment with your doctor.

Amphetamines pass into breast milk. Breastfeeding is not recommended while taking lisdexamfetamine.

Drug interactions with lisdexamfetamine

• MAOIs (e.g., phenelzine) — serious risk of hypertensive crisis and serotonin syndrome; do not use together or within 14 days of stopping an MAOI
• Other stimulants — additive cardiovascular effects; avoid combining
• Antihypertensives — lisdexamfetamine may reduce the effectiveness of blood pressure medications
• Antacids and vitamin C — may affect absorption; take lisdexamfetamine separately from high-dose vitamin C supplements and antacids
• Alcohol — avoid; alcohol may increase the risk of cardiovascular side effects

Lisdexamfetamine vs methylphenidate (Ritalin) — which is better for ADHD?

Both are effective first-line treatments for ADHD, but they differ in several ways:

• Methylphenidate (Ritalin, Rubifen, Concerta) — funded by Pharmac with Special Authority; available in short, intermediate, and long-acting forms; works differently (blocks reuptake of dopamine/noradrenaline)
• Lisdexamfetamine (Vyvanse) — not funded; one of the longest-acting ADHD medications available; smoother effect profile for many patients; amphetamine-based mechanism
• Response to ADHD medications is highly individual — some people respond better to one class than the other

How to get a prescription for Vyvanse in NZ

Because lisdexamfetamine is a controlled drug (Class B2), there are some important steps:

• A diagnosis of ADHD must be made by an appropriate clinician (paediatrician, psychiatrist, or sometimes a GP with ADHD prescribing experience)
• Your GP may prescribe Vyvanse, or you may need a specialist referral depending on your region and GP’s scope of practice
• Prescriptions for controlled stimulant drugs in NZ can only be written for up to one month’s supply at a time
• Since Vyvanse is unfunded, you will pay private pharmacy costs — typically around $120–$200 per month depending on dose

Frequently asked questions about lisdexamfetamine in NZ

Is Vyvanse available in New Zealand?
Yes. Vyvanse (lisdexamfetamine) has Medsafe consent in NZ and is available at pharmacies on private prescription.

Is lisdexamfetamine funded by Pharmac?
No. As of May 2026, lisdexamfetamine is not on the Pharmac schedule. Funded ADHD stimulant options include methylphenidate (Special Authority required) and dexamphetamine.

How does Vyvanse compare to dexamphetamine?
Dexamphetamine is the active metabolite that lisdexamfetamine converts to in the body. Dexamphetamine is available in NZ in immediate-release and some long-acting forms, and some formulations are Pharmac-funded with Special Authority. Lisdexamfetamine’s prodrug design provides smoother blood levels and potentially lower misuse risk.

📬 Get Pharmac updates by email — Join the free KiwiMeds Bulletin and we’ll notify you if Pharmac funds Vyvanse. Subscribe free →